WANDA BEARING
920002
HENDERA
831152
LINGOOD
833284
4
WUHAN LAND
830779
5
TECHVISION
832876
US Stock MarketDetailed Quotes
CMMB Chemomab Therapeutics
- 1.620
- -0.010-0.61%
Close Feb 27 16:00 ET
- 1.600
- -0.020-1.23%
Post 18:36 ET
30.55MMarket Cap-1.72P/E (TTM)
1.703High1.620Low101.87KVolume1.620Open1.630Pre Close168.85KTurnover0.86%Turnover RatioLossP/E (Static)18.86MShares2.55052wk High1.87P/B19.15MFloat Cap0.57952wk Low--Dividend TTM11.82MShs Float184.000Historical High--Div YieldTTM5.10%Amplitude0.420Historical Low1.657Avg Price1Lot Size
About Chemomab Therapeutics Company
Chemomab Therapeutics Ltd. operates as a clinical-stage biotech company. It discovers and develops therapeutics for conditions with unmet need that involve Inflammation and fibrosis. The company was founded by Adi Mor on September 22, 2011 and is headquartered in Tel Aviv, Israel.
Company Profile
SymbolCMMB
Company NameChemomab Therapeutics
Listing DateFeb 12, 2019
Issue Price11.50
Founded2011
CEODr. Adi Mor, PhD
MarketNASDAQ
Employees20
Securities TypeDR
ADS Ratio1.0 : 20.0
Fiscal Year Ends12-31
AddressKiryat Atidim,Building 7
CityTel Aviv
ProvinceTel Aviv
CountryIsrael
Zip Code6158002
Phone972-77-331-0156
Websitehttp://www.chemomab.com
Company Executives
- Name
- Position
- Salary
- Dr. Adi Mor, PhD
- Chief Executive Officer, Chief Scientific Officer and Director
- --
- Dr. Matthew B. Frankel
- Chief Medical Officer
- --
- Sigal Fattal
- Chief Financial Officer
- --
- Dr. Nissim Darvish, M.D.,PhD
- Chairman of the Board
- --
- Jill M. Quigley, Esq.
- Independent Director
- --
- Neil Cohen
- Independent Director
- --
- Dr. Claude Nicaise,M.D.
- Independent Director
- --
- Dr. Alan C. Moses, F.A.C.P.,M.D.
- Independent Director
- --
Trending Stocks
Discussing
FOMC leaves rates unchanged, how will you adjust your portfolio?
FOMC left the target Federal Funds rate unchanged at at target of 4.25%-4.5%, how will you adjust your portfolio?
Moo Live
Jan 30 03:25
FOMC Press Conference, January 29, 2025